Research Analysts Issue Forecasts for BPMC Q1 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Blueprint Medicines in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst A. Berens expects that the biotechnology company will post earnings per share of ($0.77) for the quarter. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.63) per share. Leerink Partnrs also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.49) EPS and Q4 2025 earnings at ($0.37) EPS.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%.

Several other brokerages have also recently issued reports on BPMC. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price objective on shares of Blueprint Medicines in a research note on Thursday, February 13th. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. JMP Securities restated a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Wedbush restated an “outperform” rating and set a $128.00 target price (up previously from $124.00) on shares of Blueprint Medicines in a research note on Thursday, February 13th. Finally, UBS Group began coverage on Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 target price for the company. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Blueprint Medicines has a consensus rating of “Moderate Buy” and an average price target of $123.83.

Blueprint Medicines Stock Performance

Shares of Blueprint Medicines stock opened at $92.48 on Monday. The business has a 50-day moving average of $99.54 and a 200 day moving average of $94.40. Blueprint Medicines has a 12 month low of $80.42 and a 12 month high of $121.90. The stock has a market capitalization of $5.88 billion, a price-to-earnings ratio of -43.83 and a beta of 0.62. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27.

Insiders Place Their Bets

In related news, Director Jeffrey W. Albers sold 15,000 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $89.77, for a total value of $1,346,550.00. Following the sale, the director now directly owns 157,557 shares in the company, valued at $14,143,891.89. The trade was a 8.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 49,851 shares of company stock valued at $4,984,696 over the last quarter. Company insiders own 4.21% of the company’s stock.

Institutional Trading of Blueprint Medicines

A number of institutional investors have recently bought and sold shares of the company. Pallas Capital Advisors LLC lifted its position in shares of Blueprint Medicines by 3.2% in the third quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after acquiring an additional 176 shares in the last quarter. Torray Investment Partners LLC increased its stake in Blueprint Medicines by 1.1% during the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock worth $1,439,000 after acquiring an additional 186 shares during the last quarter. Sherbrooke Park Advisers LLC boosted its position in shares of Blueprint Medicines by 8.4% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 3,374 shares of the biotechnology company’s stock worth $294,000 after buying an additional 261 shares during the period. Franklin Resources Inc. boosted its position in shares of Blueprint Medicines by 0.7% in the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after buying an additional 265 shares during the period. Finally, Summit Investment Advisors Inc. boosted its position in shares of Blueprint Medicines by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company’s stock worth $580,000 after buying an additional 283 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.